Dahl SG - Search Results

1

Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics.

Steimer JL, Dahl SG, De Alwis DP, Gundert-Remy U, Karlsson MO, Martinkova J, Aarons L, Ahr HJ, Clairambault J, Freyer G, Friberg LE, Kern SE, Kopp-Schneider A, Ludwig WD, De Nicolao G, Rocchetti M, Troconiz IF. Steimer JL, et al. Among authors: dahl sg. Eur J Cancer. 2010 Jan;46(1):21-32. doi: 10.1016/j.ejca.2009.10.011. Eur J Cancer. 2010. PMID: 19954965

2

Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework.

Dahl SG, Aarons L, Gundert-Remy U, Karlsson MO, Schneider YJ, Steimer JL, Trocóniz IF. Dahl SG, et al. Basic Clin Pharmacol Toxicol. 2010 Jan;106(1):2-12. doi: 10.1111/j.1742-7843.2009.00456.x. Epub 2009 Jul 22. Basic Clin Pharmacol Toxicol. 2010. PMID: 19686541 Free article. Review.

3

Effects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models.

Kapitulnik J, Pelkonen O, Gundert-Remy U, Dahl SG, Boobis AR. Kapitulnik J, et al. Among authors: dahl sg. Expert Opin Ther Targets. 2009 Jul;13(7):867-87. doi: 10.1517/14728220903018965. Expert Opin Ther Targets. 2009. PMID: 19530989 Review.

4

Molecular approaches to the identification of biomarkers of exposure and effect--report of an expert meeting organized by COST Action B15. November 28, 2003.

Gundert-Remy U, Dahl SG, Boobis A, Kremers P, Kopp-Schneider A, Oberemm A, Renwick A, Pelkonen O. Gundert-Remy U, et al. Among authors: dahl sg. Toxicol Lett. 2005 Apr 10;156(2):227-40. doi: 10.1016/j.toxlet.2004.11.016. Epub 2005 Jan 8. Toxicol Lett. 2005. PMID: 15737486 Review.

5

Molecular modelling of drug targets: the past, the present and the future.

Dahl SG, Sylte I. Dahl SG, et al. Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):151-5. doi: 10.1111/j.1742-7843.2005.pto960302.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 15733208 Free article. Review.

6

Bioinformatics and receptor mechanisms of psychotropic drugs.

Dahl SG, Edvardsen Ø, Kristiansen K, Sylte I. Dahl SG, et al. Biotechnol Annu Rev. 2001;7:165-77. doi: 10.1016/s1387-2656(01)07036-3. Biotechnol Annu Rev. 2001. PMID: 11686043 Review.

7

Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.

Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. Danhof M, et al. Among authors: dahl sg. Pharm Res. 2005 Sep;22(9):1432-7. doi: 10.1007/s11095-005-5882-3. Epub 2005 Aug 24. Pharm Res. 2005. PMID: 16132354

8

Effect of levomepromazine and metabolites on debrisoquine hydroxylation in the rat.

Hals PA, Dahl SG. Hals PA, et al. Among authors: dahl sg. Pharmacol Toxicol. 1994 Nov;75(5):255-60. doi: 10.1111/j.1600-0773.1994.tb00357.x. Pharmacol Toxicol. 1994. PMID: 7870695

9

Structures and models of transporter proteins.

Dahl SG, Sylte I, Ravna AW. Dahl SG, et al. J Pharmacol Exp Ther. 2004 Jun;309(3):853-60. doi: 10.1124/jpet.103.059972. Epub 2004 Feb 26. J Pharmacol Exp Ther. 2004. PMID: 14988415 Review.

10

From genomics to drug targets.

Dahl SG, Sylte I. Dahl SG, et al. J Psychopharmacol. 2006 Jul;20(4 Suppl):95-9. doi: 10.1177/1359786806066088. J Psychopharmacol. 2006. PMID: 16785277 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

97 results

Search Page